Redhill Biopharma Ltd
NASDAQ:RDHL
Intrinsic Value
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. [ Read More ]
The intrinsic value of one
RDHL
stock under the Base Case scenario is
0.7723
USD.
Compared to the current market price of 0.4208 USD,
Redhill Biopharma Ltd
is
Undervalued by 46%.
Redhill Biopharma Ltd's market capitalization is 12.5m USD.
RDHL stock price is 0.4208 USD.
RDHL stock price (0.4208 USD) is 46% less than its Intrinsic Value (0.7723 USD).
RDHL. Open DCF Valuation
RDHL stock price (0.4208 USD) is 46% less than its Relative Value (0.7723 USD). Open Relative Valuation
RDHL.
RDHL's long-term assets (23m USD) exceed its long-term liabilties (21m USD).
RDHL's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 18%.
RDHL's short-term liabilties (19m USD) exceed its short-term assets (16m USD).
RDHL's Revenue has dropped by 89% over the past 12 months.
RDHL's ROE (Return on Equity) has significantly increased in the last 3 years from -170% to -103%, and is approaching profitability.
RDHL's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -75% to 18%.
RDHL has positive Operating Income for the last twelve months.
RDHL has positive Net Income for the last twelve months.
RDHL's ROE (Return on Equity) for the past 12 months is negative and is equal to -103%.
RDHL has positive Gross Profit for the last twelve months.
RDHL has negative Free Cash Flow for the last twelve months.
RDHL's Revenue has been falling by 53% per year for the last 3 years.
RDHL's D/E (Debt to Equity) is very low and is equal to 0.22.
RDHL has negative three-year average ROE (Return on Equity): -227%. The company is not efficient at transforming stockholders' equity into net income.
RDHL has negative three-year average ROIC (Return on Invested Capital): -43%. The company is not efficient at using invested capital to generate operating income.
RDHL has negative Net Debt. This means that the company has more cash and short-term investments (6m USD) than debt (455k USD).
RDHL generates enough operating income (13m USD) to cover interest payments on its debt (3m USD).
RDHL's Altman Z-Score is very low and is equal to -21.89.
Valuation Backtest
Redhill Biopharma Ltd
Run backtest to discover the historical profit from buying and selling
RDHL
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Redhill Biopharma Ltd
Balance Sheet Decomposition
Redhill Biopharma Ltd
| Current Assets | 16.1m |
| Cash & Short-Term Investments | 5.6m |
| Receivables | 2.6m |
| Other Current Assets | 8m |
| Non-Current Assets | 6.9m |
| PP&E | 1.2m |
| Intangibles | 5.6m |
| Other Non-Current Assets | 147k |
| Current Liabilities | 19.2m |
| Accounts Payable | 3.3m |
| Accrued Liabilities | 4.6m |
| Other Current Liabilities | 11.4m |
| Non-Current Liabilities | 1.7m |
| Long-Term Debt | 455k |
| Other Non-Current Liabilities | 1.3m |
Earnings Waterfall
Redhill Biopharma Ltd
|
Revenue
|
6.5m
USD
|
|
Cost of Revenue
|
-3.5m
USD
|
|
Gross Profit
|
3.1m
USD
|
|
Operating Expenses
|
9.6m
USD
|
|
Operating Income
|
12.6m
USD
|
|
Other Expenses
|
11.3m
USD
|
|
Net Income
|
23.9m
USD
|
Free Cash Flow Analysis
Redhill Biopharma Ltd
What is Free Cash Flow?
RDHL Profitability Score
Profitability Due Diligence
Redhill Biopharma Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Redhill Biopharma Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
RDHL Solvency Score
Solvency Due Diligence
Redhill Biopharma Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Score
Redhill Biopharma Ltd's solvency score is 44/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RDHL Price Targets Summary
Redhill Biopharma Ltd
Shareholder Return
RDHL Price
Redhill Biopharma Ltd
| Average Annual Return | -37.61% |
| Standard Deviation of Annual Returns | 55.77% |
| Max Drawdown | -100% |
| Market Capitalization | 12.5m USD |
| Shares Outstanding | 29 703 000 |
| Percentage of Shares Shorted | 3.06% |
Company Profile
Redhill Biopharma Ltd
Country
Industry
Market Cap
Dividend Yield
Description
RedHill Biopharma Ltd. is a biopharmaceutical company focusing gastrointestinal and infectious diseases. The firm promotes three gastrointestinal drugs in the US: Movantik, Talicia and Aemcolo. Key programs in it pipeline of late-stage clinical assets include: opaganib (Yeliva) and RHB-107 for multiple indications including COVID-19, RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease and RHB-104 for Crohn's disease.
Contact
IPO
Employees
Officers
The intrinsic value of one
RDHL
stock under the Base Case scenario is
0.7723
USD.
Compared to the current market price of 0.4208 USD,
Redhill Biopharma Ltd
is
Undervalued by 46%.
You don't have any saved screeners yet
